Curis Inc (NASDAQ:CRIS) — Market Cap & Net Worth
Market Cap & Net Worth: Curis Inc (CRIS)
Curis Inc (NASDAQ:CRIS) has a market capitalization of $8.10 Million ($8.10 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27370 globally and #5421 in its home market, demonstrating a -2.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Curis Inc's stock price $0.59 by its total outstanding shares 13734939 (13.73 Million). Analyse cash efficiency ratio of Curis Inc to see how efficiently the company converts income to cash.
Curis Inc Market Cap History: 2015 to 2026
Curis Inc's market capitalization history from 2015 to 2026. Data shows change from $4.00 Billion to $8.10 Million (-42.18% CAGR).
Index Memberships
Curis Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #798 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2589 of 3165 |
Weight: Curis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Curis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Curis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.85x
Curis Inc's market cap is 3.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.00 Billion | $7.88 Million | -$58.98 Million | 507.32x | N/A |
| 2016 | $4.23 Billion | $7.53 Million | -$60.41 Million | 562.02x | N/A |
| 2017 | $961.45 Million | $9.90 Million | -$53.32 Million | 97.14x | N/A |
| 2018 | $189.49 Million | $10.43 Million | -$32.58 Million | 18.17x | N/A |
| 2019 | $466.99 Million | $10.00 Million | -$32.14 Million | 46.68x | N/A |
| 2020 | $2.25 Billion | $10.84 Million | -$29.91 Million | 207.64x | N/A |
| 2021 | $1.31 Billion | $10.65 Million | -$45.44 Million | 122.79x | N/A |
| 2022 | $151.08 Million | $10.16 Million | -$60.32 Million | 14.87x | N/A |
| 2023 | $175.12 Million | $10.02 Million | -$47.41 Million | 17.47x | N/A |
| 2024 | $42.03 Million | $10.91 Million | -$43.39 Million | 3.85x | N/A |
Competitor Companies of CRIS by Market Capitalization
Companies near Curis Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Curis Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Curis Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Curis Inc's market cap moved from $4.00 Billion to $ 8.10 Million, with a yearly change of -42.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.10 Million | -40.23% |
| 2025 | $13.56 Million | -67.74% |
| 2024 | $42.03 Million | -76.00% |
| 2023 | $175.12 Million | +15.91% |
| 2022 | $151.08 Million | -88.45% |
| 2021 | $1.31 Billion | -41.88% |
| 2020 | $2.25 Billion | +381.76% |
| 2019 | $466.99 Million | +146.45% |
| 2018 | $189.49 Million | -80.29% |
| 2017 | $961.45 Million | -77.27% |
| 2016 | $4.23 Billion | +5.84% |
| 2015 | $4.00 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Curis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.10 Million USD |
| MoneyControl | $8.10 Million USD |
| MarketWatch | $8.10 Million USD |
| marketcap.company | $8.10 Million USD |
| Reuters | $8.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodyspla… Read more